The Indian Pharmacopoeia Commission (IPC) has signed two major partnerships to strengthen medicine quality, patient safety, and pharmaceutical standards across India’s public health system.
The first agreement, with the Pharmaceuticals & Medical Devices Bureau of India (PMBI), focuses on improving quality assurance for medicines sold through Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs). Under this framework, PMBI will send randomly selected batches of Jan Aushadhi medicines to IPC for independent quality testing. This is aimed at ensuring that low-cost generic medicines supplied through the Jan Aushadhi network meet the same safety and efficacy standards expected of all regulated drugs.
The partnership also integrates the Pharmacovigilance Programme of India (PvPI) into Jan Aushadhi stores by introducing QR-code-based reporting and a dedicated toll-free helpline for patients to report adverse drug reactions (ADRs). Pharmacists will also be encouraged to use the National Formulary of India (NFI) to promote rational prescribing and reduce misuse of medicines.
The second MoU, signed with NIPER Hajipur, focuses on advanced pharmaceutical research. The collaboration will focus on impurity profiling, specifically genotoxic impurities like nitrosamines and work on developing reference standards for biologics, biosimilars, and cell and gene therapies. By linking impurity profiling with ADR data, the partnership aims to establish stronger evidence-based pharmacopoeial limits and improve regulatory standards for next-generation medicines.
Together, these measures shift the focus from affordable medicine access alone to a stronger system of verified quality, patient safety, and future-ready pharmaceutical regulation.
Key Strategic Focus Areas
Random Quality Audits: PMBI to submit randomly selected Jan Aushadhi batches to IPC for rigorous quality verification.
Digital Pharmacovigilance: Display of PvPI QR codes and a dedicated toll-free number (1800-180-3024) at PMBJKs to empower patient reporting of side effects.
Rational Drug Use: Promotion of the National Formulary of India (NFI) among pharmacists to prevent over-prescription and ensure evidence-based medicine.
Genotoxic Research: Collaborative studies on nitrosamine impurities to establish safety limits within the Indian Pharmacopoeia.
Next-Gen Standards: Development of reference standards for biosimilars and emerging gene therapies, moving beyond traditional chemical drugs.
Institutional Synergy: Faculty and instrument sharing between IPC and NIPER Hajipur to optimize public research infrastructure.
What is "Pharmacovigilance"?
Pharmacovigilance is the science and activities related to detecting, assessing, understanding, and preventing adverse effects or any other medicine-related problems. While a drug is tested before it hits the market, some side effects only appear when millions of people start taking it.
In the context of the IPC–PMBI MoU, pharmacovigilance turns every Jan Aushadhi Kendra into a "listening post." By scanning a QR code, a patient can report an unexpected reaction directly to the government. This data helps the IPC decide if a drug needs a new warning label, a dosage change, or even a recall, ensuring long-term safety for the public.
Policy Relevance
Building Trust in Generics: By subjecting Jan Aushadhi medicines, which are 50% to 90% cheaper than branded versions, to random IPC testing, the government is providing a "gold standard" seal of quality that builds public confidence in affordable generics.
Ensuring Patient Safety: Integrating PvPI into the PMBJK network creates the world's largest community-based drug safety monitoring system, essential for a country with India's diverse demographic.
Preparing for the Biologics Boom: The focus on biosimilars and gene therapy standards with NIPER Hajipur ensures that the Indian Pharmacopoeia remains future-ready as the domestic industry shifts from simple chemicals to complex biological drugs.
Global Regulatory Risks: Proactive research into nitrosamine impurities aligns India with global standards (like the USFDA and EMA), protecting Indian pharma exports from "quality alerts" and bans in international markets.
Strengthening Human Capital: The internship and fellowship programs bridge the gap between academic research at NIPER and regulatory practice at IPC, creating a specialized workforce for the Viksit Bharat 2047pharma vision.
Relevant Question for Policy Stakeholders: How can the Jan Aushadhi network move from periodic quality testing to real-time batch traceability by linking IPC verification, QR-based authentication, and patient ADR reporting into a single public-facing platform?
Follow The Full News Here: PIB: IPC Signs MoUs to Promote Drug Quality, Research, and Patient Safety